Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

DUBAI, United Arab Emirates — A French citizen imprisoned in Iran for over 880 days has been freed and is back home, French officials said Thursday. The release of Olivier Grondeau came as ...

A French citizen imprisoned in Iran for more than 880 days has been freed, President Emmanuel Macron has announced. The release of Olivier Grondeau comes as France and the rest of Europe attempt ...

Vertex Pharmaceuticals (VRTX) is a key player, leveraging CRISPR/Cas9 and stem cell technology to tackle type 1 diabetes (T1D) at its root. Its VX-880 therapy has demonstrated the ability to restore ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands ...

It’s especially sharp in second-from-top VX trim with its black wheels, matched on our tester to black metallic paint. WATCH: Paul’s video review of the 2025 Toyota LandCruiser Prado Kakadu Not only ...